- Home
- COE vs UNCY Comparison
COE vs UNCY Comparison
Compare COE & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COE | UNCY |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.1M | 146.8M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | COE | UNCY |
|---|---|---|
| Price | $19.30 | $6.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 2.8K | ★ 417.3K |
| Earning Date | 03-20-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.60 | $0.45 |
| 52 Week High | $56.13 | $7.57 |
Technical Indicators
Market Signals| Indicator | COE | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 21.20 | 51.42 |
| Support Level | $17.90 | $6.48 |
| Resistance Level | $30.97 | $7.36 |
| Average True Range (ATR) | 1.09 | 0.32 |
| MACD | -0.68 | -0.01 |
| Stochastic Oscillator | 1.86 | 46.98 |
Price Performance
Historical ComparisonAbout COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.